Search clinical trials for: metformin extended release

Total 7770 results

Sandoz

Completed

To Demonstrate the Relative Bioavailability of Metformin HCL 500 mg Extended Release (XR) Tablets Under Fasting Conditions

Type II Diabetes
Boehringer Ingelheim
Eli Lilly and Company

Completed

Bioequivalence of a Fixed Dose Combination Tablet of Empagliflozin/Metformin Extended Release Compared With Mono Compound Tablets in Healthy Male and Female

Healthy

Germany
Boehringer Ingelheim
Eli Lilly and Company

Completed

Relative Bioavailability of 2 Fixed Dose Combinations of Empagliflozin/Metformin Extended Release (XR) Compared With Single Tablets

Healthy

United States
Boehringer Ingelheim
Eli Lilly and Company

Completed

Bioequivalence of a Fixed Dose Combination Tablet of Empagliflozin/Metformin Extended Release Compared With Mono Compound Tablets in Healthy Subjects

Healthy

Germany
Janssen Research & Development, LLC

Completed

A Study to Assess the Bioequivalence of the Metformin Component of the Fixed Dose Combination Tablet of Canagliflozin and Metformin Extended Release (XR) With Respect to Metformin XR Tablet Coadministered With Canagliflozin in Healthy Fed and Fasted Participants

Healthy

United States
Janssen Research & Development, LLC

Completed

A Study to Assess the Bioequivalence of the Metformin Component of the Fixed Dose Combination Tablet of Canagliflozin and Metformin Extended Release With Respect to Metformin XR Tablet Coadministered With Canagliflozin in Healthy Fed and Fasted Participants

Healthy

United States
Merck KGaA, Darmstadt, Germany

Completed

Metformin Extended Release Versus Metformin Immediate Release in Subjects With Type 2 Diabetes (CONSENT)

Diabetes Mellitus, Type 2

Germany
Catholic University of the Sacred Heart

Unknown

Extended-release vs Immediate-release Metformin in PCOS Women

Polycystic Ovary Syndrome

Italy
Janssen Research & Development, LLC

Completed

A Study to Assess the Bioequivalence of the Metformin Component of the Fixed Dose Combination Tablet of Canagliflozin and Metformin Extended Release With Respect to Metformin XR Tablet Co-administered With Canagliflozin in Healthy Fed and Fasted Participants

Healthy

United States
Janssen Research & Development, LLC

Completed

A Study to Assess the Bioequivalence of the Metformin Component of the Fixed Dose Combination Tablet of Canagliflozin and Metformin Extended Release With Respect to Metformin Extended Release Tablet Coadministered With Canagliflozin in Healthy Fed and Fasted Participants

Healthy

United States
Boehringer Ingelheim
Eli Lilly and Company

Completed

Bioequivalence of a FDC Tablet of Linagliptin/Metformin (2.5mg/1000mg) Extended Release in Healthy Subjects.

Healthy

Germany
Boehringer Ingelheim
Eli Lilly and Company

Completed

Bioequivalence of a FDC Tablet of Linagliptin/Metformin (5mg/1000mg) Extended Release in Healthy Subjects

Healthy

Germany
Boehringer Ingelheim
Eli Lilly and Company

Completed

Bioequivalence of a FDC Tablet of Linagliptin/Metformin (2.5mg/750mg) Extended Release in Healthy Subjects

Healthy

Germany
LG Life Sciences

Unknown

BE Study of the Combinations of Gemigliptin 50mg and Metformin HCl Extended Release 2000mg in Comparison to Each Component Administered Alone

Healthy

Korea, Republic of
M.D. Anderson Cancer Center

Terminated

An Open-Labeled Pilot Study of Biomarker Response Following Short-Term Exposure to Metformin

Colorectal Carcinoma

United States
AstraZeneca

Completed

Bioequivalence Study of Fixed-dose Combinations and Coadministered Individual Tablets of Saxagliptin/Metformin-Brazil

Type 2 Diabetes Mellitus

Brazil
LG Life Sciences

Completed

BE Study of the Combinations of Gemigliptin 50mg and Metformin HCl Extended Release 1000mg in Comparison to Each Component Administered Alone

Healthy

Korea, Republic of
University of Hawaii
National Institute of General Medical Sciences (NIGMS)

Unknown

Metformin for HIV Inflammation

Coronary Artery Disease | HIV

United States
LG Life Sciences

Completed

BE Study of the Combinations of Gemigliptin 50mg and Metformin HCl Extended Release 500mg in Comparison to Each Component Administered Alone

Healthy

Korea, Republic of
Janssen Research & Development, LLC

Completed

A Bioequivalence Study of the Fixed Dose Combination Tablets of Canagliflozin and Metformin Extended Release (XR) With Respect to the Individual Components

Healthy Volunteers

United States
Janssen Research & Development, LLC

Completed

A Bioequivalence Study of the Fixed Dose Combination Tablets of Canagliflozin and Metformin Extended Release (XR) With Respect to the Individual Components in Healthy Fed Participants

Healthy

United States
Janssen Research & Development, LLC

Completed

A Bioequivalence Study of the Fixed Dose Combination Tablets of Canagliflozin and Metformin Extended Release (XR) With Respect to the Individual Components in Healthy Fed Participants

Healthy

United States
Janssen Research & Development, LLC

Completed

A Bioequivalence Study of the Fixed Dose Combination Tablets of Canagliflozin and Metformin Extended Release (XR) With Respect to the Individual Components

Healthy Volunteers

United States
LG Life Sciences

Completed

BE Study of the Combinations of Gemigliptin 50mg and Metformin HCl Extended Release 1000mg in Comparison to Each Component Administered Alone.

Healthy

Korea, Republic of
Mayo Clinic
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); National... and other collaborators

Completed

Effect of Insulin Sensitizer Therapy on Atherothrombotic and Inflammatory Profiles Associated With Insulin Resistance

Metabolic Syndrome | Insulin Resistance | Type 2 Diabetes

United States
IPCA Laboratories Ltd.

Completed

Bioequivalence Study of Metformin Hydrochloride Extended-Release Tablets USP 750 mg Under Fasting Condition

Fasting

India
IPCA Laboratories Ltd.

Completed

Bioequivalence Study of Metformin Hydrochloride Extended-Release Tablets USP 750 mg Under Fed Condition

Fasting

India
M.D. Anderson Cancer Center

Withdrawn

Prospective Trial of Metformin - Chemoprevention Role

Colorectum
Lawson Health Research Institute
Canadian Institutes of Health Research (CIHR)

Completed

Activity and Metformin Intervention in Obese Adolescents (REACH)

Obesity | Type 2 Diabetes

Canada
Dexa Medica Group

Completed

Bioequivalence Study of Two Formulations of 500 mg Metformin Extended Release Tablet

Metformin XR BE Study in Healthy Volunteers With Single and Multiple Dose

Indonesia
Torrent Pharmaceuticals Limited

Completed

Bioequivalence Study of Metformin Hydrochloride Extended Release 750 mg Tablets Versus Glucophage XR® 750 mg Tablet in Healthy Volunteers Under Fasting Conditions.

Type 2 Diabetes

India
Torrent Pharmaceuticals Limited

Completed

Bioequivalence Study of Metformin Hydrochloride Extended Release 750 mg Tablets Versus Glucophage XR® 750 mg Tablet in Healthy Volunteers Under Fed Conditions.

Type 2 Diabetes
Torrent Pharmaceuticals Limited

Completed

Study to Compare the Bioavailability of Extended Release Metformin HCl Tablet Versus Glucophage XR® Tablets in Healthy Human Volunteers Under Fasting Condition

Type 2 Diabetes

India
Torrent Pharmaceuticals Limited

Completed

Bioequivalence Study of Metformin Hydrochloride Extended Release 500 mg Tablet Versus Glucophage XR® 500 mg Tablet in Healthy Volunteers Under Fed Conditions

Type 2 Diabetes

India
Era's Lucknow Medical College

Completed

Metformin in Overweight Type 2 Diabetes Mellitus

Obesity | Type 2 Diabetes Mellitus

India
Ranbaxy Laboratories Limited

Completed

Bioequivalence Study of Metformin HCl 750 mg XR Under Fasting Conditions

Healthy

United States
Ranbaxy Laboratories Limited

Completed

Bioequivalence Study of Metformin HCl 750 mg XR Tablets Under Non Fasting Conditions

Healthy

United States
AbbVie

Not yet recruiting

A Study to Assess Relative Bioavailability and Food Effect of ABBV-668 Extended-Release Formulations in Adult Participants

Healthy Volunteers
University of Kansas Medical Center

Not yet recruiting

Knee Osteoarthritis Treatment With Zilretta vs. Kenalog in the Context of Type II Diabetes

Diabetes Mellitus, Type 2 | Osteoarthritis, Knee

United States
Xiangya Hospital of Central South University

Not yet recruiting

Efficacy and Safety of Early Initiation of Butylphthalide Treatment in Patients With Acute Ischemic Stroke.

Acute Ischemic Stroke
University of Florida
University of Colorado, Denver; University of Miami

Not yet recruiting

Precision Administration of Anti-thymocyte Globulin With or Without Verapamil

Type 1 Diabetes

United States
Applied Science & Performance Institute

Recruiting

Acute Effects of PLT Health Solutions zümXR Extended-Release Caffeine

Cognitive Change | Mood | Caffeine | Mood Change

United States
Brigham and Women's Hospital
University of Utah

Not yet recruiting

Extended-release Buprenorphine as a Novel Low-dose Induction Strategy

Opioid Use Disorder
Syneos Health
Asieris Pharmaceuticals (AUS) Pty Ltd.

Not yet recruiting

A Study of APL-1501 Extended Release Capsules Compared to APL-1202 Immediate Release Tablets in Healthy Volunteers

Healthy Volunteers
Bostal Drug Delivery Co., Ltd

Not yet recruiting

A Study to Evaluate Safety, Tolerability and pK of Semaglutide ER Injectable Suspension in Healthy, Adult Human Subjects

Diabetes Mellitus, Type 2
Lei Lei, MD

Recruiting

Neurofeedback-Based Digital Therapeutics for the Diagnosis and Treatment of ADHD in Children. (ADHD)

Attention Deficit Disorder With Hyperactivity | Executive Function Disorder

China
Lifespan
National Institute on Drug Abuse (NIDA)

Recruiting

Injectable Extended-Release Buprenorphine (XR-B) in a Correctional Setting: Qualitative Interviews

Opioid Use Disorder | Treatment Adherence and Compliance | Criminal Justice

United States
Peking University First Hospital
Jiangsu Hengrui Pharmaceutical Co., Ltd.; Beijing Biote Pharmaceutical Co.,Ltd

Recruiting

Adjuvant Rezvilutamide in Combination With Androgen Deprivation Therapy in Androgen Receptor-positive, High-risk Salivary Duct Carcinoma

Salivary Gland Neoplasm Duct

China
Teva Branded Pharmaceutical Products R&D, Inc.

Recruiting

Open-label Trial Characterizing the PK of 3 SC Olanzapine Extended-release Formulations in Participants With Schizophrenia/Schizoaffective Disorder

Schizophrenia, Schizoaffective Disorder

United States
Friends Research Institute, Inc.

Not yet recruiting

Buprenorphine for Individuals in Jail

Opioid Use Disorder

United States

3

Subscribe